Imatinib

Generic Name: Imatinib

Brand Names: Gleevec, Glivec, Imatinib Teva, Imatinib Accord

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₁N_₇O

CAS Number: 152459-95-5

Unique Ingredient Identifier: BKJ8M8G5HI

Background: Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and typically occurred in the first four weeks of therapy".. The discovery of imatinib also established a new group of therapy called "targeted therapy", since treatment can be tailored specifically to the unique cancer genetics of each patient.

Indication: Imatinib is indicated for the treatment of adult and pediatric chronic myeloid leukemia with Philadelphia chromosome mutation (Ph+) in blast crisis, accelerated phase, or chronic phase after IFN-alpha therapy failure.Additionally, imatinib is also indicated to treat adult and pediatric Ph+ acute lymphoblastic leukemia, adult myelodysplastic/myeloproliferative diseases, adult aggressive systemic mastocytosis, adult hypereosinophilic syndrome and/or chronic eosinophilic leukemia (CEL), adult dermatofibrosarcoma protuberans, and malignant gastrointestinal stromal tumors (GIST).

Associated Conditions: Accelerated Phase Chronic Myelogenous Leukemia (CML), Aggressive Systemic Mastocytosis, Chordomas, Chronic Eosinophilic Leukemia, FIP1L1-PDGFRα fusion kinase status unknown Chronic eosinophilic leukemia, FIP1L1-PDGFRα fusion kinase status unknown Hypereosinophilic syndrome, Gastrointestinal Stromal Tumor (GIST), Hypereosinophilic Syndrome (HES), Metastatic Gastrointestinal Stromal Tumor (GIST), Metastatic Melanoma, Myelodysplastic Syndrome, Myeloproliferative Disorders (MPD), Refractory Acute Lymphoblastic Leukemia (ALL), Blast phase Chronic myeloid leukemia, CKit mutational status unknown Aggressive systemic mastocytosis, Metastatic Dermatofibrosarcoma protuberans, Newly diagnosed Acute Lymphoblastic Leukaemia, Newly diagnosed, chronic phase Chronic myeloid leukemia, Recurrent Dermatofibrosarcoma protuberans, Refractory, chronic phase Chronic myeloid leukemia, Unresectable Gastrointestinal stromal tumor

Associated Therapies: -

Clinical Trials

Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor

Phase 2

Completed

Conditions: Gastrointestinal Stromal Tumor

Interventions: Procedure: Conventional Surgery
Drug: Imatinib Mesylate

First Posted Date: 2003-01-27

Last Posted Date: 2020-10-26

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 63

Registration Number: NCT00028002

Locations: 🇺🇸
Radiation Therapy Oncology Group, Philadelphia, Pennsylvania, United States

Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia

Phase 3

Completed

Conditions: Recurrent Childhood Acute Lymphoblastic Leukemia
Childhood Acute Lymphoblastic Leukemia in Remission

Interventions: Biological: filgrastim
Drug: asparaginase
Drug: cyclophosphamide
Drug: cyclosporine
Drug: cytarabine
Drug: daunorubicin hydrochloride
Drug: dexamethasone
Drug: etoposide
Drug: ifosfamide
Drug: imatinib mesylate
Drug: leucovorin calcium
Drug: mercaptopurine tablet
Drug: methotrexate
Drug: pegaspargase
Drug: vincristine sulfate
Procedure: allogeneic bone marrow transplantation
Procedure: peripheral blood stem cell transplantation
Procedure: umbilical cord blood transplantation
Radiation: radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2014-02-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 220

Registration Number: NCT00022737

Locations: 🇺🇸
Children's Oncology Group, Arcadia, California, United States

Imatinib Mesylate in Treating Patients With Myelofibrosis

Phase 2

Completed

Conditions: Chronic Myelomonocytic Leukemia
Polycythemia Vera
Essential Thrombocythemia
Primary Myelofibrosis

Interventions: Drug: imatinib mesylate
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2014-02-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 18

Registration Number: NCT00039416

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Imatinib Mesylate in Treating Patients With Recurrent Meningioma

Phase 2

Completed

Conditions: Adult Meningioma
Adult Meningeal Hemangiopericytoma
Adult Grade II Meningioma
Adult Grade I Meningioma
Adult Grade III Meningioma
Recurrent Adult Brain Tumor

Interventions: Drug: imatinib mesylate
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2003-01-27

Last Posted Date: 2017-05-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 23

Registration Number: NCT00045734

Locations: 🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸
National Cancer Institute Neuro-Oncology Branch, Bethesda, Maryland, United States

and more 4 locations

Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

Phase 2

Completed

Conditions: Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Relapsing Chronic Myelogenous Leukemia
Chronic Phase Chronic Myelogenous Leukemia

Interventions: Biological: oblimersen sodium
Drug: imatinib mesylate
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 43

Registration Number: NCT00049192

Locations: 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States

Imatinib Mesylate in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer

Phase 2

Completed

Conditions: Primary Peritoneal Cavity Cancer
Recurrent Ovarian Epithelial Cancer

Interventions: Drug: imatinib mesylate
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-02-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT00041041

Locations: 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States

Combination Chemotherapy and Imatinib Mesylate in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Phase 1

Completed

Conditions: Lung Cancer

Interventions: Drug: cisplatin
Drug: imatinib mesylate
Drug: irinotecan hydrochloride

First Posted Date: 2003-01-27

Last Posted Date: 2015-07-23

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 9

Registration Number: NCT00052494

Locations: 🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada

Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma

Phase 2

Completed

Conditions: Childhood Malignant Fibrous Histiocytoma of Bone
Sarcoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-19

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00031915

Locations: 🇺🇸
Herbert Irving Comprehensive Cancer Center at Columbia University, New York, New York, United States
🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

and more 7 locations

Chemotherapy, Imatinib Mesylate, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Phase 2

Completed

Conditions: Adult Acute Lymphoblastic Leukemia in Remission

Interventions: Drug: imatinib mesylate
Drug: methotrexate
Drug: vincristine sulfate
Drug: leucovorin calcium
Procedure: peripheral blood stem cell transplantation
Procedure: autologous hematopoietic stem cell transplantation
Procedure: allogeneic hematopoietic stem cell transplantation
Radiation: total-body irradiation
Drug: tacrolimus
Biological: filgrastim
Drug: etoposide
Drug: cyclophosphamide
Drug: cytarabine
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2014-11-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 58

Registration Number: NCT00039377

Locations: 🇺🇸
Great Falls Clinic, Great Falls, Montana, United States
🇺🇸
Mason District Hospital, Havana, Illinois, United States
🇺🇸
Berdeaux, Donald MD (UIA Investigator), Great Falls, Montana, United States

and more 94 locations

Imatinib Mesylate in Treating Patients With Salivary Gland Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: imatinib mesylate

First Posted Date: 2003-01-27

Last Posted Date: 2019-02-15

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 16

Registration Number: NCT00045669

Locations: 🇺🇸
Oncology/Hematology Associates of Central Illinois, P.C., Peoria, Illinois, United States
🇺🇸
LaGrange Memorial Hospital, LaGrange, Illinois, United States
🇺🇸
University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States

and more 12 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy